Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

SI-BONE (SIBN) stock in plain English

Free brief · no signupStart here
SIBNPublished Nov 18, 2026
SI-BONE Inc
Healthcare · Medical Devices
Manufactures titanium implant systems used by orthopedic surgeons to treat lower back pain. Sells these triangular implants and related surgical instruments directly to hospitals.
Assets:
iFuse product lineflagship triangular titanium implants for joint fusion
Pelvic fixation portfoliohardware including Bedrock implants for spinal support
Santa Clara headquartersprimary corporate office and training facility in California
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

70
OPS ScoreOperating finances
Latest quote
+0.89%$23.75
$1.07B
n/a (loss)
$220.46M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was SIBN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does SI-BONE (SIBN) do?

SI-BONE Inc (SIBN) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures titanium implant systems used by orthopedic surgeons to treat lower back pain. Sells these triangular implants and related surgical instruments directly to hospitals. Develops and sells specialized implant systems specifically designed for fusion of the sacroiliac joint. It is worth $1.07B on the market and sold $220.46M over the last year.

Market cap
$1.07B
P/E ratio
None (reported a loss)
Annual sales
$220.46M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 18, 2026

Brands and businesses behind SIBN

  • iFuse: Triangular titanium implants that generate revenue when purchased by hospitals for sacroiliac joint fusion procedures.
  • iFuse Bedrock: Specialized sacropelvic screws that generate sales when used by surgeons during complex adult spinal deformity operations.
  • iFuse TORQ: Threaded titanium implants that generate revenue from pelvic fracture repairs and joint stabilization procedures.

SIBN’s flags, in plain English

Each flag is a number from SI-BONE’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 7.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 79.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Low debt

Low debt, only 23% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -6.2%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about SIBN

How big is SI-BONE?

SI-BONE’s market cap is $1.07B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $220.46M: what customers paid the company over the last year, before any costs.

What is SIBN’s P/E ratio?

SIBN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with SIBN?

The company generates recurring net losses and relies heavily on ongoing revenue growth to reach operating profitability. That is one risk on SI-BONE’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From SI-BONE’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SIBN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card